Literature DB >> 27671487

Dendrimer nanoarchitectures for cancer diagnosis and anticancer drug delivery.

Ashok Kumar Sharma1, Avinash Gothwal1, Prashant Kesharwani2, Hashem Alsaab3, Arun K Iyer4, Umesh Gupta5.   

Abstract

Dendrimers are novel nanoarchitectures with unique properties including a globular 3D shape, a monodispersed unimicellar nature and a nanometric size range. The availability of multiple peripheral functional groups and tunable surface engineering enable the facile modification of the dendrimer surface with different therapeutic drugs, diagnostic agents and targeting ligands. Drug encapsulation, and solubilizing and passive targeting also equally contribute to the therapeutic use of dendrimers. In this review, we highlight recent advances in the delivery of anticancer drugs using dendrimers, as well as other biomedical and diagnostic applications. Taken together, the immense potential and utility of dendrimers are envisaged to have a significant positive impact on the growing arena of drug delivery and targeting.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27671487     DOI: 10.1016/j.drudis.2016.09.013

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  17 in total

Review 1.  Nanocarrier-Based Therapeutics and Theranostics Drug Delivery Systems for Next Generation of Liver Cancer Nanodrug Modalities.

Authors:  Umme Ruman; Sharida Fakurazi; Mas Jaffri Masarudin; Mohd Zobir Hussein
Journal:  Int J Nanomedicine       Date:  2020-03-03

Review 2.  Use of magnetic fields and nanoparticles to trigger drug release and improve tumor targeting.

Authors:  Jessica F Liu; Bian Jang; David Issadore; Andrew Tsourkas
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2019-06-26

Review 3.  Engineering exosomes as refined biological nanoplatforms for drug delivery.

Authors:  Xin Luan; Kanokwan Sansanaphongpricha; Ila Myers; Hongwei Chen; Hebao Yuan; Duxin Sun
Journal:  Acta Pharmacol Sin       Date:  2017-04-10       Impact factor: 6.150

4.  Design, Synthesis, and Biological Evaluations of Asymmetric Bow-Tie PAMAM Dendrimer-Based Conjugates for Tumor-Targeted Drug Delivery.

Authors:  Tao Wang; Yaozhong Zhang; Longfei Wei; Yuhan G Teng; Tadashi Honda; Iwao Ojima
Journal:  ACS Omega       Date:  2018-04-03

5.  Design, Synthesis, and Characterization of Fully Zwitterionic, Functionalized Dendrimers.

Authors:  Esther Roeven; Luc Scheres; Maarten M J Smulders; Han Zuilhof
Journal:  ACS Omega       Date:  2019-02-11

6.  Synthesis and Characterization of FITC Labelled Ruthenium Dendrimer as a Prospective Anticancer Drug.

Authors:  Sylwia Michlewska; Małgorzata Kubczak; Marta Maroto-Díaz; Natalia Sanz Del Olmo; Paula Ortega; Dzmitry Shcharbin; Rafael Gomez Ramirez; Francisco Javier de la Mata; Maksim Ionov; Maria Bryszewska
Journal:  Biomolecules       Date:  2019-08-25

Review 7.  Overcoming Hurdles in Nanoparticle Clinical Translation: The Influence of Experimental Design and Surface Modification.

Authors:  Jacob W Shreffler; Jessica E Pullan; Kaitlin M Dailey; Sanku Mallik; Amanda E Brooks
Journal:  Int J Mol Sci       Date:  2019-11-30       Impact factor: 5.923

Review 8.  Dendrimers: Amazing Platforms for Bioactive Molecule Delivery Systems.

Authors:  Claudia Sandoval-Yañez; Cristian Castro Rodriguez
Journal:  Materials (Basel)       Date:  2020-01-24       Impact factor: 3.623

Review 9.  Nanodrug Delivery Systems for the Treatment of Ovarian Cancer.

Authors:  Jonathan M Pantshwa; Pierre P D Kondiah; Yahya E Choonara; Thashree Marimuthu; Viness Pillay
Journal:  Cancers (Basel)       Date:  2020-01-15       Impact factor: 6.639

10.  First Class of Phosphorus Dendritic Compounds Containing β-Cyclodextrin Units in the Periphery Prepared by CuAAC.

Authors:  Kendra Sorroza-Martínez; Israel González-Méndez; Mireille Vonlanthen; Kathleen I Moineau-Chane Ching; Anne-Marie Caminade; Javier Illescas; Ernesto Rivera
Journal:  Molecules       Date:  2020-09-04       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.